Aren't we special!

The FDA has updated the indication of naloxegol (Movantik, AstraZeneca) tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain to include patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

 

Exactly what we were told last week on the WebEx, that it was a class change. Dope.